| Trial ID # | NCT00551070 |
| Phase | II |
| Drug Class | Signaling Pathway Inhibitors: RAS-RAF-MEK-ERK/MEK |
| Drug Name | Selumetinib |
| Alternate Drug Names | ARRY-142886, AZD6244, Koselugo |
| Drugs in Trial | Selumetinib |
| Eligible Participant | Recurrent low-grade serous ovarian or peritoneal carcinoma |
| Patients Enrolled | 52 |
| Therapy Setting | Recurrence |
| Study Design | Open-Label, Non-randomized |
| Endpoints | ORR, PFS, OS, evaluated per RECIST |
| Biomarkers | Exploratory: RAS, BRAF, p-ERK/ERK protein |
| Efficacy | ORR: 15.4% (1CR, 7PR, n=52) |
| Clinically Significant Adverse Events | Serious AE: cardiac (2%), pulmonary (2%) |
| Conclusion | Promising activity in patients with low grade serous ovarian cancer; No significant correlation of response with BRAF or RAS mutations, but analysis performed on primary tumor specimen |
| Reference | Farley J et al. Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. Lancet Oncol (2013) 14(2):134-40 |
Starting
January 1, 2025,
Clearity is joining
Ovarian Cancer
Research Alliance
(OCRA) and this website
will be redirected to
www.ocrahope.org
OCRA and Clearity are committed to serving the ovarian cancer community and providing the education, information, and support people need.